786578-60-7

Basic information

• Product Name: N-[Amino(imino)methyl]-4-phenylpiperazine-1-carboximidamide
• Synonyms: N-(diaminomethylene)-4-phenyl-piperazine-1-carboxamidine;N-(diaminomethylidene)-4-phenyl-piperazine-1-carboximidamide;N-(diaminomethylidene)-4-phenylpiperazine-1-carboximidamide;N-[Amino(imino)methyl]-4-phenylpiperazine-1-carboximidamide;N-(diaminomethylene)-4-phenyl-1-piperazinecarboxamidine;N-[Imino-(4-phenyl-piperazin-1-yl)-methyl]-guanidine
• CAS NO: 786578-60-7
• Molecular Formula: C₁₂H₁₈N₆
• Molecular Weight: 246.31152
• Mol File: 786578-60-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[Amino(imino)methyl]-4-phenylpiperazine-1-carboximidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[Amino(imino)methyl]-4-phenylpiperazine-1-carboximidamide(786578-60-7)
• EPA Substance Registry System: N-[Amino(imino)methyl]-4-phenylpiperazine-1-carboximidamide(786578-60-7)

Safety Data

• Hazardous Substances Data: 786578-60-7(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 127099-85-8 N-Cyanoguanidine 

Downstream Products

• 871332-24-0 methyl {4-[{[2-amino-4-(4-phenylpiperazin-1-yl)-1,3,5-triazin-6-yl]methyl}amino]benzoyl}methioninate 
• 871332-19-3 4-({[2-amino-4-(4-phenylpiperazin-1-yl)-1,3,5-triazin-6-yl]methyl}methylamino)benzoic acid 
• 871332-16-0 4-({[2-amino-4-(4-phenylpiperazin-1-yl)-1,3,5-triazin-6-yl]methyl}amino)benzoic acid 
• 871332-12-6 2-amino-4-(4-phenylpiperazin-1-yl)-6-(1-bromomethyl)-1,3,5-triazine 
• 870126-90-2 2-[4-amino-6-(4-phenylpiperazin-1-yl)-1,3,5-triazin-2-yl]acetonitrile 

Relevant articles and documents

Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents

The discovery of a novel class of HCV inhibitors is described. The new amidinourea compounds were designed as isosteric analogues of the antiviral drug moroxydine. The two derivatives 11g and 11h showed excellent HCV inhibition activity and viability and proved to inhibit a step(s) of the RNA replication. The new compounds have been synthesized in only three synthetic steps from cheap building blocks and in high yields, thus turning to be promising drug candidates in the development of cheaper HCV treatments.